How TRIPS benefits Indian industry and how it may not benefit the Indian people
The accession to TRIPS post-2005 is a milestone in the history of India’s pharmaceutical industry whichever way you look at it. Easy access, through reverse engineering, to innovator drugs marketed abroad has been stopped. Indian industry, if it still wants to make drugs under international patents, has to buy technologies for those new innovator drugs if they are on sale; enter into exclusive marketing/voluntary license arrangements, or apply for a compulsory license (CL) and hope that it is granted.
There are currently no refbacks.